Catalyst Wire Dossier Catalyst Wire Dossier

ILEVRO

nepafenac · Novartis Pharmaceuticals Corporation
Drug timelines are a Plus or Pro feature.

11 regulatory and trial events tracked for ILEVRO, covering 2012-10-16 to 2019-04-01. Get the full timeline:

Most recent: Clinical Trial Update: Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial [Phase 4]

See pricing